The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Following this approval, Sarclisa is the first anti-CD38 therapy in combination with VRd for treating transplant-ineligible NDMM patients. A regulatory filing is currently under review in the EU ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...

Other innovative medicines like Nexviazyme, Rezurock, and Sarclisa continue to perform well and are contributing to a total of EUR1.4 billion in sales for this quarter alone. These results show ...

The Biden administration gave Israel 30 days to increase the flow of aid, warning that aid shipments into Gaza in September had reached an alarmingly low level. By Liam Stack and Aaron Boxerman ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...